“Core SG&A growth in the full year was driven by continued disciplined investment to support global market expansion and disease awareness for key assets including Arexvy, Nucala, Shingrix and Jemperli, and investment behind long-acting HIV medicines, with the phasing of this investment weighted more in Q4 2024. 2024 growth was partly offset by a 1 percentage point favourable impact of the reversal of the legal provision taken in Q1 2023 for the Zejula royalty dispute, following a successful appeal.”

Investments behind long-acting HIV medicines.

Hmmm